Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Akouos, Inc. AKUS |
RA CAPITAL MANAGEMENT L.P. | 2,281,249 6.600% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | BCLS Acquisition Corp. BLSA |
RA CAPITAL MANAGEMENT L.P. | 1,250,000 8.400% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
RA CAPITAL MANAGEMENT L.P. | 2,805,045 5.400% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2020-12-31 | 13G | 5:01 Acquisition Corp. FVAM |
RA CAPITAL MANAGEMENT L.P. | 750,000 8.700% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | GH Research PLC GHRS |
RA CAPITAL MANAGEMENT L.P. | 2,843,757 5.500% |
-135,198 (-4.54%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
RA CAPITAL MANAGEMENT L.P. | 2,613,623 5.300% |
2,613,623 (New Position) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Concert Pharmaceuticals, Inc. CNCE |
RA CAPITAL MANAGEMENT L.P. | 3,510,103 9.990% |
1,686,583 (+92.49%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Geron Corporation GERN |
RA CAPITAL MANAGEMENT L.P. | 32,388,799 9.990% |
1,273,858 (+4.09%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST |
RA CAPITAL MANAGEMENT L.P. | 2,246,503 7.500% |
-81,211 (-3.49%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Frazier Lifesciences Acquisition Corporation FLAC |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-1,000,000 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | ImmunoGen, Inc. IMGN |
RA CAPITAL MANAGEMENT L.P. | 22,162,958 9.990% |
3,745,500 (+20.34%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Novavax, Inc. NVAX |
RA CAPITAL MANAGEMENT L.P. | 2,097,794 2.800% |
-1,690,770 (-44.63%) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
RA CAPITAL MANAGEMENT L.P. | 1,742,186 4.970% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-388,385 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT |
RA CAPITAL MANAGEMENT L.P. | 3,350,506 9.500% |
103,389 (+3.18%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
RA CAPITAL MANAGEMENT L.P. | 1,930,322 7.900% |
530,833 (+37.93%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR |
RA CAPITAL MANAGEMENT L.P. | 1,334,610 7.500% |
-180,541 (-11.92%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Verona Pharma plc VRNA |
RA CAPITAL MANAGEMENT L.P. | 48,778,172 9.990% |
7,235,168 (+17.42%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
RA CAPITAL MANAGEMENT L.P. | 37,867 3.900% |
-20,401 (-35.01%) |
Filing History |
| 2022-01-10 5:00 pm Purchase |
2021-12-29 | 13G | Pardes Biosciences, Inc. PRDS |
RA CAPITAL MANAGEMENT L.P. | 4,431,901 7.100% |
4,431,901 (New Position) |
Filing History |